Cabaletta Bio, Inc. reported its cash and cash equivalents decreased to $131.8 million as of March 31, 2025, from $164.0 million at the end of 2024, and expects this will sustain operations through the first half of 2026. Additionally, they announced a planned 2027 submission for a BLA following recent FDA alignment on registrational cohorts, shared in a press release on May 15, 2025.